在109例儿科泛性皮囊性牛皮的临床特征和长期结果.
Jiaying Li1,2, Zhaoyang Wang1,2, Chaoyang Miao1,2
1Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
概括
儿科发病的泛性性牛皮 (PGPP) 发作随着年龄的增长而减少,但仍然很常见. 较早发病的PGPP与更频繁的爆发有关,生物药物现在是主要的治疗方法.
科学领域:
- 皮肤病学 皮肤病学
- 儿科免疫学 儿科免疫学
- 临床研究 临床研究
背景情况:
- 儿科发病的泛性性牛皮 (PGPP) 是一种罕见的,具有挑战性的炎症状况.
- 它的特点是反复爆发和复杂的管理需求.
研究的目的:
- 审查PGPP的临床特征.
- 分析耀斑模式并识别触发因素.
- 评估当前和不断发展的治疗选择.
主要方法:
- 对109名PGPP患者 (2006-2023) 的回顾性分析.
- 通过医疗记录和电话调查收集数据.
- 分析爆发频率,持续时间,触发因素和治疗方式.
主要成果:
- 中位发病年龄为6岁;男性患病率更高.
- 呼吸道感染是最常见的触发因素.
- 发作频率和持续时间随着年龄的增长而减少;较早发作与更高频率相关.
- 在2020年之前,常规疗法 (乙二) 是常见的; 生物药物 (secukinumab) 现在是普遍存在的.
结论:
- 随着年龄的增长,PGPP火焰往往会减少,但复发是频繁的.
- 早期发病的PGPP可能与发作频率的增加有关.
- 生物药物代表了PGPP目前的护理标准.
相关概念视频
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
COPD: Pathogenesis and Clinical Features
1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Pharmacokinetics in Pediatric Patients: Drug Excretion
196
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
Endocarditis II: Clinical Features of Infective Endocarditis
381
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
381
Pharmacokinetics in Pediatric Patients: Drug Metabolism
179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
Pharmacokinetics in Pediatric Patients: Drug Distribution
247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247


